Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of ...
KUALA LUMPUR, Oct 23 (Bernama) -- Recursion, a clinical stage TechBio company, announced the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral ...
Salt Lake City-based Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has secured an irrevocable commitment from Evotec SE, a significant shareholder of Exscientia plc, to support Recursion's proposed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results